

- 20 Padrik P: Prognostic factors of immunotherapy in metastatic renal cell carcinoma. *Med Oncol* 2003;20:325–334.
- 21 Hofmann H, Neef H, Krohe K, Andreev P, Silber R: Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. *Eur Urol* 2005;48:77–82.
- 22 Alves A, Adam R, Majno P, Delvart V, Azoulay D, Castaing D, Bismuth H: Hepatic resection for metastatic renal tumors: is it worthwhile? *Ann Surg Oncol* 2003;10:705–710.
- 23 Lau WK, Zincke H, Lohse CM, Cheville JC, Weaver AL, Blute ML: Contralateral adrenal metastasis of renal cell carcinoma: treatment, outcome and a review. *BJU Int* 2003;91:775–779.
- 24 Harada Y, Nonomura N, Kondo M, Nishimura K, Takahara S, Miki T, Okuyama A: Clinical study of brain metastasis of renal cell carcinoma. *Eur Urol* 1999;36:230–235.
- 25 van der Poel HG, Roukema JA, Horenblas S, van Geel AN, Debruyne FM: Metastasectomy in renal cell carcinoma: a multicenter retrospective analysis. *Eur Urol* 1999;35:197–203.
- 26 de Kernion JB, Ramming KP, Smith RB: The natural history of metastatic renal cell carcinoma: a computer analysis. *J Urol* 1978;120:148–152.
- 27 O'Brien MF, Rea D, Rogers E, Bredin H, Butler M, Grainger R, McDermott TE, Mullins G, O'Brien A, Twomey A, Thornhill J: Interleukin-2, interferon- $\alpha$  and 5-fluorouracil immunotherapy for metastatic renal cell carcinoma: the all Ireland experience. *Eur Urol* 2004;45:613–618.
- 28 Negrier S: Better survival with interleukin-2-based regimen? Possibly only in highly selected patients. *J Clin Oncol* 2004;22:1174–1176.
- 29 Bennett RT, Lerner SE, Taub HC, Dutcher JP, Fleischmann J: Cytoreductive surgery for stage IV renal cell carcinoma. *J Urol* 1995;154:32–34.

## Announcement

---

### C.E. Alken Prize 2006

C.E. Alken Foundation Council

The C.E. Alken Foundation supports clinical and experimental research in the field of urology through an annual prize for outstanding scientific work.

The C.E. Alken Prize is awarded for the best unpublished scientific work in the field of urology and may be divided. The prize comprises a certificate and the sum of CHF 10,000.

Manuscripts may be submitted in either English or German. Seven copies of the manuscript should be sent to the following address and marked for the attention of:

Mr. E. Hauser, Advocate  
C.E. Alken Foundation  
Kellerhals Solicitors  
Kappellenstrasse 14  
CH–3011 Bern (Switzerland)

The deadline for submission of manuscripts is September 1, 2006. Each paper has to be marked with a code word and must not include the name of the author. An additional sealed envelope (marked on the outside with the code word) has to be enclosed and must contain the following:

- Curriculum vitae of the author (max. 3 pages).
- Structured summary of the manuscript (aim of study, material/methods, results, conclusions).

The award winner will be determined by the Foundation Council, whose decision is final.